Tags

Type your tag names separated by a space and hit enter

Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study.
Eur J Intern Med. 2010 Aug; 21(4):297-300.EJ

Abstract

BACKGROUND

Oral anticoagulant therapy with vitamin K antagonists is associated with an increased risk of bleeding, particularly gastrointestinal bleeding. It remains unclear, however, whether use of these medications is a risk factor for subarachnoid haemorrhage (SAH). We therefore examined the association between oral vitamin K antagonist use and risk of SAH.

METHODS

We conducted this population-based case-control study using medical databases in Northern Denmark (population 1,150,000). We identified 1188 patients admitted to neurologic or neurosurgical departments with a first-time diagnosis of SAH between 1996 and 2008 and 11,880 population controls. We obtained information on use of vitamin K antagonists, other medication use, and comorbidity. We used logistic regression analysis to compute odds ratios (ORs) comparing oral anticoagulant users and non-users, controlling for potential confounding factors.

RESULTS

9 cases (0.8%) and 157 controls (1.3%) were current users of vitamin K antagonists (at least one prescription filled within 90 days of the diagnosis/index date). Current use of vitamin K antagonists was not associated with increased SAH risk compared with non-use [adjusted OR=0.80 (95% CI: 0.37-1.74)]. Changing the exposure window from 90 days to 120 days or to 60 days before the diagnosis/index date did not change the estimate substantially.

CONCLUSION

We found no evidence to support an association between use of vitamin K antagonists and increased SAH risk.

Authors+Show Affiliations

Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, Aarhus N, Denmark. mo@dce.au.dkNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20603039

Citation

Olsen, Morten, et al. "Use of Vitamin K Antagonists and Risk of Subarachnoid Haemorrhage: a Population-based Case-control Study." European Journal of Internal Medicine, vol. 21, no. 4, 2010, pp. 297-300.
Olsen M, Johansen MB, Christensen S, et al. Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. Eur J Intern Med. 2010;21(4):297-300.
Olsen, M., Johansen, M. B., Christensen, S., & Sørensen, H. T. (2010). Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. European Journal of Internal Medicine, 21(4), 297-300. https://doi.org/10.1016/j.ejim.2010.04.009
Olsen M, et al. Use of Vitamin K Antagonists and Risk of Subarachnoid Haemorrhage: a Population-based Case-control Study. Eur J Intern Med. 2010;21(4):297-300. PubMed PMID: 20603039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. AU - Olsen,Morten, AU - Johansen,Martin Berg, AU - Christensen,Steffen, AU - Sørensen,Henrik Toft, PY - 2010/01/06/received PY - 2010/04/14/revised PY - 2010/04/25/accepted PY - 2010/7/7/entrez PY - 2010/7/7/pubmed PY - 2010/11/10/medline SP - 297 EP - 300 JF - European journal of internal medicine JO - Eur J Intern Med VL - 21 IS - 4 N2 - BACKGROUND: Oral anticoagulant therapy with vitamin K antagonists is associated with an increased risk of bleeding, particularly gastrointestinal bleeding. It remains unclear, however, whether use of these medications is a risk factor for subarachnoid haemorrhage (SAH). We therefore examined the association between oral vitamin K antagonist use and risk of SAH. METHODS: We conducted this population-based case-control study using medical databases in Northern Denmark (population 1,150,000). We identified 1188 patients admitted to neurologic or neurosurgical departments with a first-time diagnosis of SAH between 1996 and 2008 and 11,880 population controls. We obtained information on use of vitamin K antagonists, other medication use, and comorbidity. We used logistic regression analysis to compute odds ratios (ORs) comparing oral anticoagulant users and non-users, controlling for potential confounding factors. RESULTS: 9 cases (0.8%) and 157 controls (1.3%) were current users of vitamin K antagonists (at least one prescription filled within 90 days of the diagnosis/index date). Current use of vitamin K antagonists was not associated with increased SAH risk compared with non-use [adjusted OR=0.80 (95% CI: 0.37-1.74)]. Changing the exposure window from 90 days to 120 days or to 60 days before the diagnosis/index date did not change the estimate substantially. CONCLUSION: We found no evidence to support an association between use of vitamin K antagonists and increased SAH risk. SN - 1879-0828 UR - https://www.unboundmedicine.com/medline/citation/20603039/Use_of_vitamin_K_antagonists_and_risk_of_subarachnoid_haemorrhage:_a_population_based_case_control_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(10)00085-3 DB - PRIME DP - Unbound Medicine ER -